Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC3 | Q13507 | 1/20 | 0.33 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23487858 | 0.78 | NAE1 (0.30) | — | |
| SCHEMBL23456120 | 0.78 | NAE1 (0.30) | — | |
| SCHEMBL23487494 | 0.78 | NAE1 (0.30) | — | |
| SCHEMBL23456026 | 0.77 | EPHX2 (0.34) | — | |
| SCHEMBL27253227 | 0.77 | EPHX2 (0.34) | — | |
| SCHEMBL24166573 | 0.77 | EPHX2 (0.34) | — | |
| SCHEMBL23487869 | 0.77 | EPHX2 (0.34) | — | |
| SCHEMBL23455967 | 0.77 | EPHX2 (0.34) | — | |
| SCHEMBL23456280 | 0.72 | — | — | |
| SCHEMBL23487940 | 0.72 | STING1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | TRPC3 333/4885TRPC6 867/4885 |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | TRPC3 333/4885TRPC6 867/4885 |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | TRPC3 333/4885TRPC6 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.